Newsgroup: it.economia.borsa
Titolo: CELL: NE PARLA ANCHE IL SOLE 24 ORE: DALLA FINANZA CREATIVA ALLA FINANZA ATOMICA...

ADESSO NE PARLA ANCHE IL SOLE 24 ORE: DALLA FINANZA CREATIVA ALLA FINANZA 
ATOMICA
Alla ricerca dell'atomo
la continuità aziendale di una società che a un patrimonio netto negativo
per 133 miloni di dollari, perdite accumalate per 1,27 miliardi di dollari e
ricavi risibili (130 mila dollari nel 2007) non è scontata. Ma la
bio-farmaceutica Cell Therapeutics, società italo-americana che ha inventato
la "ricapitalizzazione a getto continuo" per sopravvivere a decenni di
perdite, resterà comunque nella storia. Il titolo, che ha perso i riquisiti
della quotazione al nasdaq, è uno degli strumenti finanziari che ha
conosciuto il deprezzamento più lungo e importante nella storia dei mercati,
Chi ha investito in Cell Therapeutics ai prezzi di 2,94 dollari (ottobre
2000) a fine 2007 era già rovinato (18,8 dollari per azione) Ma al peggio
non c'è fine: nel 2008 il titolo è caduto ancora del 99%, fino a 14
centesimi di dollaro,e dopo i primi 20 giorni del 2009 (-31%) non vale più
neanche un penny (0,09 dolari). Da adesso in poi si entra nella finanza
"atomica"
-- 
__________________________________
Quando l'ultimo albero sarà stato abbattuto,
l'ultimo fiume avvelenato,
l'ultimo pesce pescato,
l'ultimo animale libero ucciso...
Vi accorgerete che non si può mangiare il denaro.
(Nativi Cree). 

 ha scritto nel messaggio
news:Ialdl.249082$FR.5...@twister1.libero.it...


 "atomica"
ahah tanto fanno lo split 1-100 a febbraio ahahah

 ha scritto nel messaggio
news:4fldl.1230$8Z....@tornado.fastwebnet.it...

raggruppamento max 1-20
fra un po non servirà nemmeno quello

> ahah tanto fanno lo split 1-100 a febbraio ahahah
stavolta non basta, ne serve uno almeno da milla a uno per reggere qualche 
mese.....
... ma chissà sti xyotax e pixantrone che fine faranno... alla fine verranno 
approvati dalla FDA e una big pharma se compra tutto a due dollari...
... tzè 

 bello anche l'articolo uscito a SEATTLE
che dice?? che dice??
dicce .. dicce...

http://community.seattletimes.nwsource.com/reader_feedback/public/display.php?thread=63541&offset=0#post_154099


Seattle biotech rewards execs after stock dropped 99 percent
Even in a disastrous year on Wall Street, Cell Therapeutics stood out in
2008. Its stock price dropped 99. 25 percent.
By Rami Grunbaum
Deputy business editor and Seattle Times Business staff
PREV  of  NEXT
James A. Bianco, President and CEO of Cell Therapeutics. James Bianco
Enlarge this photo
CELL THERAPEUTICS
James A. Bianco, President and CEO of Cell Therapeutics. James Bianco
Even in a disastrous year on Wall Street, Cell Therapeutics stood out in
2008. Its stock price dropped 99.25 percent.
But the cash-strapped Seattle biotech's top five executives had reason to
celebrate Dec. 31: That day they were awarded year-end bonuses totaling more
than $1 million.
Chief Executive James Bianco, who has run the company since founding it in
1992, was awarded a $487,500 bonus to supplement his $650,000 salary and
other perks.
Cell Therapeutics' eight board members, who include Bianco, chose to pay 75
percent of the bonuses in cash, and will decide March 1 whether "the company
is sufficiently liquid to pay the remaining amount." In other words, the
board wasn't certain Cell Therapeutics would be able to spare the $250,000
to complete its New Year's gift to top management.
Here's another way to put the bonuses in context: Cell Therapeutics' market
capitalization is about $27 million, according to Bloomberg. If Starbucks
(which had a difficult 2008 but only lost half its stock value) gave its top
five officers a bonus equal to one-twentyseventh of its market cap, the
execs would walk off with about $270 million.
Cell Therapeutics is Seattle's oldest surviving public biotech and has the
longest-reigning CEO. The company has lost a remarkable $1.3 billion over
the past 16 years, with no sign of stopping. Its board chairman since 2006
is longtime director Philip Nudelman, the former president and CEO of Group
Health Cooperative.
Company spokesman Dan Eramian, one of the five New Year's Eve awardees, says
that "in this market environment, stock prices are not valid measures of
company performance." He defends the bonus awards, saying executives at the
110-employee company have not had a raise in their base salary since 2005.
During that period, however, Cell Therapeutics has been an even bigger loser
than Washington Mutual, as shares went from a split-adjusted $310 on Jan. 1,
2005, to the current penny-stock level, 11 cents on Friday.
And, Bianco had the highest base salary of all the local biotech leaders,
including companies with 30 times the market value of Cell Therapeutics.
Eramian points out that in 2008, the company advanced several drug
applications in the regulatory pipeline.
"We have the potential to have three drugs on the market this year. That
could be very good news for cancer patients," he says.
But Cell Therapeutics has a track record of generating only slim sales with
drugs it has brought to market, and investors apparently aren't impressed.
advertising
Cell Therapeutics entered 2008 with its auditors declaring there was
"substantial doubt" over its ability to survive financially. It ended the
September quarter with $218 million in liabilities, including convertible
debt with interest rates as high as 18 percent.
The company restructured some of its debt late last year, staving off big
imminent payments that it couldn't make. The rejiggering involved pumping
out vast quantities of new stock, which quadrupled the total shares just
since November and severely diluted pre-existing shareholders; this past
week it issued 38 million shares to clear away obligations over a company it
bought in 2007.
Eramian says that "despite the daunting and unique credit crunch biotech
companies are in, we amassed the capital we needed, accomplished a list of
remarkable milestones and got closer to the goal line."
New Year's Eve brought the company another milestone. It renewed the
contract for CEO Bianco for two more years.
Bianco got no raise, but he retained the perks he enjoyed in his previous
contract: $500 a month for a health-club membership and $3,500 a year for
tax-preparation help.
Such added benefits for Bianco cost the company $13,069 in 2007. A larger
cost to Cell Therapeutics - $146,320 in 2006 and $79,804 in 2007 - came from
so-called gross-up payments to Bianco, which offset the taxes he owed on
those and other benefits, such as family members riding along without charge
on company-chartered airplane trips.
Beginning this year, there will be no gross-up payments, however. That's one
frill the company is eliminating as it continues its fight to live another
year.
This past week a much younger Seattle medical-technology company, Northstar
Neuroscience, decided to liquidate and distribute its remaining cash to
stockholders.
That move followed months of pressure from an investment fund with major
stock ownership, which in December wrote to Northstar board members: "It
would seem that some of you remain content to pay yourselves salaries from
cash that belongs to stockholders while contributing nothing of any positive
value in return."
With Cell Therapeutics, which has few, if any, institutional shareholders
left since it became a penny stock, it's unlikely there's anyone to write
that kind of letter.

 "atomica"
ne avete parlato spesso  qui  .
Sarei  curioso  di sapere  da chi  ha investito  
in azioni CELL  quali  possibilita ci ha visto  .
Mi  interessa  conoscere  i  processi  mentali altrui.
-- 
questo articolo e` stato inviato via web dal servizio gratuito 
http://www.newsland.it/news
 segnala gli abusi ad 
ab...@newsland.it

 Mi  interessa  conoscere  i  processi  mentali altrui.
UNA OPERAZIONE FISCALE PER CHI AVEVA TROPPE PLUSVALENZE
DA ABBATTERE. 

 DA ABBATTERE.
capito.


 mentali altrui.
A me interesse sapere dove è andata in vacanza la mia mente in quel 
periodo.
Mi avesse mandato una cartolina...
..